共 50 条
- [31] Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with non-alcoholic fatty liver diseaseJOURNAL OF HEPATOLOGY, 2017, 66 (01) : S671 - S671Daniels, S. J.Nielsen, M. J.Krag, A.Eslam, M.Karsdal, M. A.Leeming, D. J.George, J.
- [32] N-terminal propeptide of type III collagen (PRO-C3) based risk for liver fibrosis predict cardiovascular events in non-alcoholic fatty liver diseaseJOURNAL OF HEPATOLOGY, 2022, 77 : S161 - S161Baratta, FrancescoTozzi, GiuliaPastori, DanieleColantoni, AlessandraCocomello, NicholasCecchi, StefanoCoronati, MattiaAngelico, FrancescoDel Ben, Maria
- [33] Serum markers of interstitial matrix formation (PRO-C3) and basement membrane remodeling (PRO-C4 and C4M) predict recurrence of fibrosis and survival in post-liver transplanted patientsJOURNAL OF HEPATOLOGY, 2019, 70 (01) : E199 - E200Nielsen, Mette JuulVillesen, IdaGudmann, NatasjaLeeming, DianaKrag, AleksanderKarsdal, MortenSurabattula, RambabuZimmermann, TimSchuppan, Detlef
- [34] Type III collagen pro-peptides (PRO-C3) as a proposed prognostic biomarker of risk of survival outcomes in clinical trials of patients with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Willumsen, NicholasNissen, Neel IngemannKarsdal, Morten Asser
- [35] PRO-C3, GP73 AND THEIR COMBINATION ACCURATELY ASSESS SIGNIFICANT AND ADVANCED FIBROSIS IN CHRONIC HEPATITIS B PATIENTSGASTROENTEROLOGY, 2024, 166 (05) : S1613 - S1613Chen, QianqianYeo, Yee HuiHu, XinyuZhu, LiRui, FajuanYin, ShengxiaZhu, ChuanwuWu, ChaoNguyen, Mindie H.Li, Jie
- [36] Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis CLIVER INTERNATIONAL, 2015, 35 (02) : 429 - 437Nielsen, Mette J.Veidal, Sanne S.Karsdal, Morten A.Orsnes-Leeming, Diana J.Vainer, BenGardner, Stephen D.Hamatake, RobertGoodman, Zachary D.Schuppan, DetlefPatel, Keyur
- [37] AMINO TERMINAL STRUCTURE AND CLEAVAGE OF GUINEA-PIG PRO-C3MOLECULAR IMMUNOLOGY, 1982, 19 (11) : 1357 - 1357GOLDBERGER, GTHOMAS, MLTACK, BFWILLIAM, JABRAHAM, GN
- [38] Soluble TREM2 and PRO-C3 as efficacy of intervention markers in NASHJOURNAL OF HEPATOLOGY, 2023, 78 : S657 - S658Wernberg, CharlotteChandran, Vineesh IndiraLauridsen, MetteSkytthe, Maria KlojgaardHansen, Camilla DalbyHansen, Johanne KraghGronkjaer, Lea LadegaardJacobsen, BirgitteDi Caterino, TinaDetlefsen, SonkeThiele, MajaGuiliani, Alejandro MayorcaLeeming, DianaKarsdal, MortenVillesen, IdaGraversen, JonasKrag, Aleksander
- [39] PRO-C3 based sequential algorithm can screen high-risk NASH and severe fibrosis in asian NAFLD populationJOURNAL OF HEPATOLOGY, 2022, 77 : S431 - S432Tang, Liang-JieLi, GangEslam, MohammedZhu, Pei-WuChen, Sui-DanLeung, Howard Ho-WaiHuang, Ou-YangWong, Grace Lai-HungZhou, Yu-JieKarsdal, MortenLeeming, DianaByrne, ChrisTargher, GiovanniGeorge, JacobWong, Vincent Wai-SunZheng, Ming-Hua
- [40] Analyses of fibrosis biomarkers PRO-C3 and ELF in resmetirom treated patients from MAESTRO-NASH, a 52 Week NASH/MASH serial liver biopsy studyJOURNAL OF HEPATOLOGY, 2024, 80 : S509 - S509Anstee, Quentin M.Schattenberg, Jorn M.Taub, RebeccaLabriola, DominicZhang, HangHennan, Jim